Philips acquires Wellcentive, boosts connected care offerings

Royal Philips ($PHG) will acquire population health management software company Wellcentive to complement Philips’ already extensive population health management offerings. The HealthTech giant already has cloud-based systems that bring together and analyze clinical, claims and financial data across hospitals and health systems.

The aim is to “help care providers deliver coordinated care that meets new healthcare quality requirements and reimbursement models,” Philips said in a statement. Philips already offers home monitoring, enterprise telehealth, personal emergency response systems (PERS) and other personal health services to help with a range of issues including intensive ambulatory care and personal health programs.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

While financial details were not disclosed, Philips did explain in the announcement that Wellcentive’s approximately 115 employees will become a part of the population health management group. Wellcentive’s CEO, Tom Zajac, will be in place to lead this group.

“Wellcentive’s solutions will provide our customers with the ability to collect data from large populations, detect patterns, assess risks and then deploy care programs tailored to the needs of specific groups,” Jeroen Tas, Philips’ CEO of connected care and health informatics, said in the announcement.

Wellcentive’s apps will be bundled into the Philips HealthSuite cloud, which houses the likes of the Intensive Ambulatory Care program. This program brings together population health management software and telehealth tech to help those offering and recieving care at home.

- here's the announcement

Related Articles:
Philips readies for mid- to high-single-digit HealthTech growth with reorg, lighting disposal
Philips, Pegasystems partner to boost device and wearable connectivity
Philips nabs 5% growth in HealthTech with connected care and informatics leading

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.